Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCX 1236
- Development stage
- Preclinical
- Lead developer
- NicOx
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
NCX 1236 is a preclinical-stage, orally administered small molecule designed as a nitric oxide (NO)-donating derivative of gabapentin. It was developed by Nicox for the treatment of neuropathic pain, including painful diabetic neuropathy. The compound is engineered to release both gabapentin and NO after oral administration. Gabapentin acts on voltage-gated calcium channels to reduce neuronal excitability, while the NO component is intended to enhance analgesic efficacy by modulating pain pathways involved in neuropathic pain. Preclinical studies demonstrated that NCX 1236 provided superior anti-allodynic effects compared to equimolar doses of gabapentin in models of lesion-induced and diabetic neuropathic pain[2][4][5].
- Other names
- nitric oxide-donating gabapentin
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on NCX 1236.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCX 1236.